DDrare: Database of Drug Development for Rare Diseases

228. 閉塞性細気管支炎
［臨床試験数：92，薬物数：125（DrugBank：34），標的遺伝子数：33，標的パスウェイ数：152］

Searched query = "Bronchiolitis obliterans", "Obliterating bronchiolitis"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.

Drug = 5-Methyl-1-Phenyl-2-1-(H)-Pyridone; AZITHROMYCIN; AZITHROMYCIN DIHYDRATE; AZITHROMYCINE; AZITHROMYCINE 250 mg; AZM; Adipate; Aerolised Liposomal Ciclosporin A; Aerolised Liposomal Ciclosporin A 10mg; Aerolised Liposomal Ciclosporin A 5mg; Azithromycin; Azithromycin (Zitromax°); Azithromycin + N-acetylcystein + inhaled corticosteroid; Azithromycine; Aztreonam; Aztreonam Lysine for Inhalation (AZLI); Basiliximab; Bortezomib; Budesonide; Budesonide/formoterol; CICLOSPORIN A; COLECALCIFEROL; Certican; Certican 0,5; Certican 0,5 mg Tabletten; Certican 0,75mg; Certican 0,75mg Tabletten; Chloride; Ciclosporin; Ciclosporin (Ciclosporinium); Ciclosporina; Ciclosporina / Ciclosporin; Ciclosporina A Liposomica Aerolised Liposomal Ciclosporin A; Ciclosporina/ Ciclosporin; Ciclosporine; Ciclosporine A; Ciclosporine, Ciclosporina; Ciclosporine, ciclosporina; Clarithromycin; Cloruro de Sodio; Cloruro de sodio; Colecalciferol; CsA; Cyclosporine; Cyclosporine A dry powder inhalation (Drug); Cyclosporine Inhalation Solution; Cyclosporine Inhalation Solution (CIS); D-Cure; D-cure; ERL080; Enteric coated mycophenolate sodium; Erythromycin; Esbriet; Etanercept; Everolimus; FAM Therapy; Fluticasone; Fluticasone propionate; Formoterol; Formoterol/Budesonide; Glucocorticoid; Helium; Helium-3; Hp 129Xenon; Hyperpolarized Helium-3 MRI; INTERFERON GAMMA-1B; Imukin; Inhalation; Interferon Gamma; Interferon gamma 1b; Interferon gamma-1b; Itacitinib; Itacitinib Adipate; L-CsA; Lactose; Liposomal Cyclosporine A; Liposomal Cyclosporine A 10 mg; Liposomal Cyclosporine A 5 mg; Liposomal aerosol cyclosporine; Lysine; MONTELUKAST SODIUM; MPH966; MSCs; Mesenchymal stem cell 0.5; Mesenchymal stem cell 1.0; Montelukast; Montelukast Teva; Montelukast sodium; Montelukast teva; Mycophenolate; Myfortic; Nintedanib; OFEV; OTHER SOURCES; Other: EIT; Other: Inhaled Hyperpolarized Xenon-129; Other: Salbutamol nebulisation and with CPAP; Other: standard immune suppression, oral; PIRFENIDONE; Pirfenidone; Pirfenidone 267 MG [Esbriet]; Prednisone; Procedure: Pulmonary function testing; Procedure: Status Post Lung Transplant; RAD001; Ruxolitinib; Salbutamol; Seretide; Singulair; Singulair (Montelukast Sodium); Sodium Chloride; Sodium Chloride Solution; Sodium Chloride Solvent; Sodium Chloride solvent; Sodium chloride; Solucion de Cloruro de Sodio; Solucion de cloruro de sodio Sodium Chloride Solution; Solvente Cloruro de Sodio Sodium Chloride Solvent; Solvente de Cloruro de Sodio; Symbicort; Tacrolimus; Vitamin D; Xenon; Zithromax; Zitromax

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT02669251 (ClinicalTrials.gov)	April 28, 2016	29/1/2016	Alvelestat (MPH966), an Oral Neutrophil Elastase Inhibitor, in Bronchiolitis Obliterans Syndrome After Allogeneic Hematopoietic Stem Cell Transplantation	A Phase 1b/2 Study of Alvelestat (MPH966), an Oral Neutrophil Elastase Inhibitor, in Bronchiolitis Obliterans Syndrome After Allogeneic Hematopoietic Stem Cell Transplantation	Chronic Graft vs Host Disease;Chronic Graft-Versus-Host-Disease;Bronchiolitis Obliterans Syndrome	Drug: MPH966	National Cancer Institute (NCI)	NULL	Recruiting	18 Years	99 Years	All	34	Phase 1;Phase 2	United States

No.

TrialID

Date_
enrollment

Date_
registration

Public_title

Scientific_title

Condition

Intervention

Primary_
sponsor

Secondary_
sponsor

Recruitment_
Status

Inclusion_
agemin

Inclusion_
agemax

Inclusion_
gender

Target_
size

Phase

Countries

NCT02669251
(ClinicalTrials.gov)

April 28, 2016

29/1/2016

Alvelestat (MPH966), an Oral Neutrophil Elastase Inhibitor, in Bronchiolitis Obliterans Syndrome After Allogeneic Hematopoietic Stem Cell Transplantation

A Phase 1b/2 Study of Alvelestat (MPH966), an Oral Neutrophil Elastase Inhibitor, in Bronchiolitis Obliterans Syndrome After Allogeneic Hematopoietic Stem Cell Transplantation

Chronic Graft vs Host Disease;Chronic Graft-Versus-Host-Disease;Bronchiolitis Obliterans Syndrome

Drug: MPH966

National Cancer Institute (NCI)

NULL

Recruiting

18 Years

99 Years

All

Phase 1;Phase 2

United States